Last reviewed · How we verify
coadministration of JP-1366 and naproxen — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
coadministration of JP-1366 and naproxen (coadministration of JP-1366 and naproxen) — Onconic Therapeutics Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| coadministration of JP-1366 and naproxen TARGET | coadministration of JP-1366 and naproxen | Onconic Therapeutics Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- coadministration of JP-1366 and naproxen CI watch — RSS
- coadministration of JP-1366 and naproxen CI watch — Atom
- coadministration of JP-1366 and naproxen CI watch — JSON
- coadministration of JP-1366 and naproxen alone — RSS
Cite this brief
Drug Landscape (2026). coadministration of JP-1366 and naproxen — Competitive Intelligence Brief. https://druglandscape.com/ci/coadministration-of-jp-1366-and-naproxen. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab